Literature DB >> 29316193

Thrombocytopenia in high-risk patients with antiphospholipid syndrome.

E Pontara1, A Banzato1, E Bison1, M G Cattini1, G Baroni1, G Denas1, A Calligaro2, P Marson3, T Tison3, A Ruffatti2, V Pengo1.   

Abstract

Essentials The prevalence of thrombocytopenia in patients with antiphospholipid syndrome is not well defined. We studied triple positive patients with antiphospholipid syndrome and its catastrophic variant. Prevalence of thrombocytopenia was 6% and 100% in patients who developed the catastrophic form. In triple positive patients thrombocytopenia is low and platelets drop during the catastrophic form.
SUMMARY: Background Thrombocytopenia is the most common non-criteria hematological feature in patients with antiphospholipid syndrome (APS). This condition is more common in patients with catastrophic APS (CAPS). Objectives To evaluate the prevalence of thrombocytopenia in a large series of high-risk patients with APS, and to assess the behavior of the platelet count during CAPS. Methods/Patients This was a cross-sectional study in which we analyzed the platelet counts of a homogeneous group of high-risk APS patients (triple-positive). Six of these patients developed a catastrophic phase of the disease, and the platelet count was recorded before the acute phase, during the acute phase, and at recovery. Results The mean platelet count in 119 high-risk triple-positive patients was 210 × 109 L-1 . With a cut-off value for thrombocytopenia of 100 × 109 L-1 , the prevalence of thrombocytopenia was 6% (seven patients). No difference between primary APS and secondary APS was found. In patients who suffered from CAPS, a significant decrease from the basal count (212 ± 51 × 109 L-1 ) to that at the time of diagnosis (60 ± 33 × 109 L-1 ) was observed. The platelet count became normal again at the time of complete remission (220 ± 57 × 109 L-1 ). A decrease in platelet count always preceded the full clinical picture. Conclusions This study shows that, in high-risk APS patients, the prevalence of thrombocytopenia is low. A decrease in platelet count was observed in all of the patients who developed the catastrophic form of the disease. A decrease in platelet count in high-risk APS patients should be considered a warning signal for disease progression to CAPS.
© 2018 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  catastrophic; phospholipid; platelets; syndrome; thrombocytopenia

Mesh:

Substances:

Year:  2018        PMID: 29316193     DOI: 10.1111/jth.13947

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

2.  Cardiovascular complications of catastrophic antiphospholipid syndrome: a case report and review of literature.

Authors:  Nitish Mittal; Mostafa Abohelwa; M Rubayat Rahman; Scott Shurmur
Journal:  Eur Heart J Case Rep       Date:  2022-05-11

Review 3.  Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Authors:  Andrew P Vreede; Paula L Bockenstedt; W Joseph McCune; Jason S Knight
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

4.  Antiphospholipid Syndrome-Related Pulmonary Embolism: Clinical Characteristics and Early Recognition.

Authors:  Maojing Shi; Weibo Gao; Yuebo Jin; Jihong Zhu; Yuansheng Liu; Tianbing Wang; Chun Li
Journal:  Front Cardiovasc Med       Date:  2022-07-11

5.  Pathophysiology of Antiphospholipid Syndrome.

Authors:  David Green
Journal:  Thromb Haemost       Date:  2021-11-18       Impact factor: 6.681

6.  Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index.

Authors:  Sherif Gamal; Samar Mohamed; Abdelkawy Moghazy
Journal:  Arch Rheumatol       Date:  2022-01-23       Impact factor: 1.007

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.